{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "Hyperinflammation",
      "Interleukin-6",
      "Interleukine-6",
      "SARS-COV-2",
      "SARS-CoV-2",
      "Tocilizumab"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33288230",
  "DateCompleted": {
    "Year": "2021",
    "Month": "02",
    "Day": "22"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "12"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "11",
        "Day": "27"
      }
    ],
    "Language": [
      "fre"
    ],
    "ELocationID": [
      "10.1016/j.revmed.2020.11.016",
      "S0248-8663(20)30829-8"
    ],
    "Journal": {
      "ISSN": "1768-3122",
      "JournalIssue": {
        "Volume": "42",
        "Issue": "2",
        "PubDate": {
          "Year": "2021",
          "Month": "Feb"
        }
      },
      "Title": "La Revue de medecine interne",
      "ISOAbbreviation": "Rev Med Interne"
    },
    "ArticleTitle": "[COVID-19: Still a place for tocilizumab?].",
    "Pagination": {
      "StartPage": "73",
      "EndPage": "78",
      "MedlinePgn": "73-78"
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de maladies infectieuses, h\u00f4pital Saint-Antoine, Assistance publique des H\u00f4pitaux de Paris, Paris, France; Universit\u00e9 de Paris, Paris, France. Electronic address: quentin.richier@hotmail.fr."
          }
        ],
        "LastName": "Richier",
        "ForeName": "Q",
        "Initials": "Q"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service d'h\u00e9matologie, h\u00f4pital Necker, Assistance publique des H\u00f4pitaux de Paris, Paris, France; Sorbonne universit\u00e9, Paris, France."
          }
        ],
        "LastName": "Pla\u00e7ais",
        "ForeName": "L",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de maladies infectieuses, h\u00f4pital Saint-Antoine, Assistance publique des H\u00f4pitaux de Paris, Paris, France; Sorbonne universit\u00e9, Paris, France."
          }
        ],
        "LastName": "Lacombe",
        "ForeName": "K",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 de Paris, Paris, France; Service d'h\u00e9matologie, h\u00f4pital Necker, Assistance publique des H\u00f4pitaux de Paris, Paris, France; Inserm U 1163, institut Imagine, Paris, France."
          }
        ],
        "LastName": "Hermine",
        "ForeName": "O",
        "Initials": "O"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ],
    "VernacularTitle": "COVID-19\u00a0: encore une place pour le tocilizumab\u00a0?"
  },
  "MedlineJournalInfo": {
    "Country": "France",
    "MedlineTA": "Rev Med Interne",
    "NlmUniqueID": "8101383",
    "ISSNLinking": "0248-8663"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Monoclonal, Humanized"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "IL6 protein, human"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interleukin-6"
    },
    {
      "RegistryNumber": "I031V2H011",
      "NameOfSubstance": "tocilizumab"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antibodies, Monoclonal, Humanized"
    },
    {
      "QualifierName": [
        "epidemiology",
        "pathology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Interleukin-6"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [
        "statistics & numerical data"
      ],
      "DescriptorName": "Randomized Controlled Trials as Topic"
    },
    {
      "QualifierName": [
        "drug effects",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Severity of Illness Index"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ]
}